阿法替尼治疗转移性或复发性HER2突变肺癌:一项回顾性国际多中心研究
该回顾性国际多中心研究纳入2009至2017年间欧洲、澳大利亚和北美七家中心的27例转移性或复发性HER2突变肺腺癌患者,评估阿法替尼的疗效。23例可评估患者中部分缓解率为13%(95%CI 4-33%),57%疾病稳定,30%疾病进展;中位缓解持续时间6个月,中位治疗时间3个月,中位总生存期23个月(95%CI 18-53个月)。作者认为阿法替尼活性有限,需进一步研究HER2突变生物学及开发更好的HER2靶向治疗。
要点
- 23例可评估患者中阿法替尼部分缓解率为13%(95%CI 4-33%)。
- 部分缓解见于HER2外显子20插入突变,包括YVMA插入2例和VAG插入1例。
- 中位缓解持续时间6个月(范围5-10),中位治疗时间3个月(范围1-30)。
核心结论
- 阿法替尼对HER2突变肺腺癌患者活性有限,包括既往HER2靶向治疗进展后仍可见缓解。
- 作者认为需进一步研究HER2突变肺腺癌生物学并开发更好的HER2靶向治疗。
研究设计与样本
- 回顾性国际多中心研究,纳入欧洲、澳大利亚和北美七家中心2009至2017年间接受阿法替尼治疗的转移性或复发性HER2突变肺腺癌患者。
- 共收集27例IV期或复发性HER2突变肺腺癌患者信息,其中23例可评估疗效。
主要发现
- 23例可评估患者中部分缓解3例(13%,95%CI 4-33%),疾病稳定13/23(57%),疾病进展7/23(30%)。
- 部分缓解见于HER2外显子20插入突变患者,包括YVMA插入2例和VAG插入1例。
- 2例部分缓解患者既往接受过曲妥珠单抗和帕妥珠单抗治疗。
- 中位缓解持续时间为6个月(范围5-10),中位治疗时间为3个月(范围1-30)。
- 自转移或复发性疾病诊断之日起中位总生存期为23个月(95%CI 18-53个月)。
关键数值与推荐
- 部分缓解率13%(95%CI 4-33%),基于23例可评估患者。
- 疾病稳定率57%(13/23),疾病进展率30%(7/23)。
- 中位缓解持续时间6个月(范围5-10),中位治疗时间3个月(范围1-30),中位总生存期23个月(95%CI 18-53个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: HER2 mutations occur in 1-3% of lung adenocarcinomas. With increasing use of next-generation sequencing at diagnosis, more patients with HER2-mutant tumours present for treatment. Few data are available to describe the clinical course and outcomes of these patients when treated with afatinib, a pan-HER inhibitor. METHODS: We identified patients with metastatic or recurrent HER2-mutant lung adenocarcinomas treated with afatinib among seven institutions across Europe, Australia, and North America between 2009 and 2017. We determined the partial response rate to afatinib, types of HER2 mutations, duration of response, time on treatment, and survival. RESULTS: We collected information on 27 patients with stage IV or recurrent HER2-mutant lung adenocarcinomas treated with afatinib. Of 23 patients evaluable for response, three partial responses were noted (13%, 95% confidence interval [CI] 4-33%). In addition, 57% of patients (13/23) had stable disease, and 30% (7/23) had progressive disease. We documented partial responses in patients with HER2 exon 20 insertions, including two with YVMA insertion and one with VAG insertion. Two patients with partial responses were previously treated with trastuzumab and pertuzumab. Median duration of response to afatinib was 6 months (range 5-10); median time on treatment was 3 months (range 1-30) and median overall survival from the date of diagnosis of metastatic or recurrent disease was 23 months (95% CI 18-53 months). CONCLUSIONS: Afatinib is modestly active in patients with HER2-mutant lung adenocarcinomas, including responses after progression on prior HER2-targeted therapies. However, investigations into the biology of HER2-mutant lung adenocarcinomas and development of better HER2-directed therapies are warranted.
引用
- Lai WV, Lebas L, Barnes TA, et al. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. Eur J Cancer. 2019. PMID: 30685684. doi:10.1016/j.ejca.2018.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。